JPMorgan analyst Lisa Gill lowered the firm’s price target on GoodRx (GDRX) to $5 from $6 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $6 from $7 at TD Cowen
- Trump Weekly: China to suspend some controls on rare earths
- Trump Trade: Nvidia says no active talks on selling Blackwell chip to China
- GoodRx will not partner with TrumpRx, CBS News reports
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength